These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21169326)

  • 21. Rosiglitazone and cardiovascular disease revisited.
    Davis TM; Prins JB
    Med J Aust; 2010 Aug; 193(3):134-5. PubMed ID: 20678037
    [No Abstract]   [Full Text] [Related]  

  • 22. Cardiovascular safety of low-dose rosiglitazone.
    Mikhail N
    Arch Intern Med; 2008 Jan; 168(1):109. PubMed ID: 18195204
    [No Abstract]   [Full Text] [Related]  

  • 23. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 26. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.
    George J; Hannah S; Lang CC
    Cardiovasc Ther; 2009; 27(2):83-8. PubMed ID: 19426244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European regulatory body recommends suspension of rosiglitazone.
    Cohen D
    BMJ; 2010 Sep; 341():c5291. PubMed ID: 20870700
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA advisers recommend new controls on rosiglitazone use.
    Traynor K
    Am J Health Syst Pharm; 2010 Aug; 67(16):1306-8. PubMed ID: 20689113
    [No Abstract]   [Full Text] [Related]  

  • 29. What have we learnt from the rosiglitazone saga?
    Montori VM; Shah ND
    BMJ; 2011 Mar; 342():d1354. PubMed ID: 21415102
    [No Abstract]   [Full Text] [Related]  

  • 30. [Wrong choice of antidiabetics can be disastrous].
    Sjöholm A
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2300-1. PubMed ID: 20973243
    [No Abstract]   [Full Text] [Related]  

  • 31. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 32. Response to "Rosiglitazone no longer recommended".
    Strahlman E
    Lancet; 2009 Feb; 373(9663):544. PubMed ID: 19217986
    [No Abstract]   [Full Text] [Related]  

  • 33. Rosiglitazone saga. Should we throw the baby out with the bathwater?
    McDonald C
    BMJ; 2011 Apr; 342():d2566. PubMed ID: 21511790
    [No Abstract]   [Full Text] [Related]  

  • 34. [Glitazone - mailing no 3. In response to DMW 49/2007].
    Gundel UF
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
    [No Abstract]   [Full Text] [Related]  

  • 35. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 36. Heart failure risk prompts warning labels on diabetes drugs. The concern now is whether this particular class of drugs causes other cardiovascular problems.
    Harv Womens Health Watch; 2007 Aug; 14(12):6-7. PubMed ID: 17722356
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA hearings leave doctors, patients in limbo on Avandia.
    Eggertson L; Woodward C
    CMAJ; 2010 Sep; 182(12):E559-60. PubMed ID: 20660583
    [No Abstract]   [Full Text] [Related]  

  • 38. European drug agency extends review of safety of pioglitazone.
    Moynihan R
    BMJ; 2011 Jun; 342():d4105. PubMed ID: 21715461
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA on rosiglitazone. More on advisory committee decision.
    Graham DJ; Gelperin K
    BMJ; 2010 Sep; 341():c4868. PubMed ID: 20823021
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antidiabetic with increased risk of coronary disease].
    Hjelvin E
    Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2971-2; author reply 2972. PubMed ID: 18026249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.